Skip to main content
. 2022 Jan 11;13:245. doi: 10.1038/s41467-021-27921-1

Fig. 7. Knockdown of MAPK4 sensitizes human TNBC cells to PI3K inhibitor treatments.

Fig. 7

Representative images and quantification of colony formation assay data of engineered a MDA-MB-231, b  SUM159, c HS578T, and d HCC1937 cells with 4 µg/ml Dox-induced knockdown of MAPK4 (iG2, iG4) or control (iNT). The cells were also treated with increasing doses of Pictilisib, Alpelisib, or control. e Representative images and quantification of SUM159-iNT and -ishMAPK4 cells in the colony formation assays. The cells were treated for 10 days with PI3K inhibitors Pictilisib (1 µM), Alpelisib (0.5 µM), LY294002 (2 µM), or DMSO. The right panels in a–e show quantification of colonies formed under each treatment condition described in the left panels. Data are mean ± SD (a–d) and mean ± SEM (e). Adjusted P values determined by two-way ANOVA followed by Sidak’s multiple comparisons. f Western blots on SUM159 and MDA-MB-231 cells with 4 µg/ml Dox-induced knockdown of MAPK4 (iG2, iG4) or control (iNT) cells after 10 days culturing in the presence of Alpelisib (+) or DMSO (−). Data are representative of at least three independent experiments. Source data are provided as a Source data file.